Belpointe Asset Management LLC Nektar Therapeutics Transaction History

Belpointe Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.64 - $3.15 $0 - $3	-1 Reduced 0.02%	5,495 $3,000
Q4 2022 Feb 08, 2023	BUY	$2.03 - $4.28 $11,156 - $23,522	5,496 New	5,496 $12,000
Q2 2019 Nov 22, 2019	SELL	$31.0 - $36.3 $92,039 - $107,774	-2,969 Closed	0 $0
Q1 2019 Jun 11, 2019	BUY	$31.58 - $46.35 $93,761 - $137,613	2,969 New	2,969 $100,000
Q4 2018 Mar 06, 2019	SELL	$30.43 - $56.65 $61,316 - $114,149	-2,015 Closed	0 $0

Q3 2018 Nov 23, 2018	BUY	$46.46 - $68.49 $93,616 - $138,007	2,015 New	2,015 $123,000
Q2 2018 Aug 06, 2018	SELL	$46.25 - $104.45 $91,343 - $206,288	-1,975 Closed	0 $0
Q1 2018 Aug 06, 2018	BUY	$57.4 - $108.44 $113,365 - $214,169	1,975 New	1,975 $210,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Belpointe Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Belpointe Asset Management LLC with notifications on news.